Vice President, Biometry in Cambridge

As a member of the Parabilis Medicines team, you will be part of an organization dedicated to creating extraordinary medicines for diseases with urgent unmet needs, harnessing our proprietary peptide platform to transform treatment possibilities for patients. Parabilis is a clinical-stage biopharmaceutical company dedicated to unlocking high-impact protein targets long-considered undruggable. The company has developed a new class of stabilized, cell-penetrant alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that are inaccessible to traditional drug modalities.

Headquartered in Cambridge, Mass., Parabilis is advancing a focused pipeline of multiple first-in-class therapies across both rare and common cancers. Its lead asset, zolucatetide (FOG-001), is a first-in-class, clinically validated direct inhibitor of the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors, implicated in millions of cancer cases annually, including in colorectal cancer, desmoid tumors, hepatocellular carcinoma and a range of other Wnt/β-catenin-driven tumors. In Phase 1 clinical trials, zolucatetide produced the first-ever clinical evidence that it can directly inhibit this interaction, once previously considered “undruggable” despite its role across multiple cancer types. Parabilis is also advancing investigational degraders of ERG and AR ON into clinical development for the treatment of prostate cancer, as well as progressing other preclinical programs. Backed by a recent $305 million Series F financing, Parabilis is entering an exciting phase of growth and execution.

The Vice President of Biometry will lead Parabilis’s biometrics organization, overseeing biostatistics, statistical programming, data management, clinical data science and Real-World Data to support clinical development programs from early-phase through regulatory submission. This strategic role ensures the integrity, quality, and compliance of all clinical trial data and analyses while driving innovation in data strategy and statistical methodologies. Reporting to our Chief Medical Officer, the successful candidate will serve as a key member of the Development leadership team, partnering closely with Clinical Development, Clinical Operations, Regulatory Affairs, translational/computational biology and other functions to enable data-driven decision-making and successful product development.

• Lead and develop the Biometrics organization, including biostatistics, programming, data management, and Clinical Data science, ensuring high-quality deliverables across all clinical programs and fostering a culture of scientific rigor, accountability, collaboration and innovation.
• Oversee design and implementation of statistical methodologies for clinical trials.
• Champion innovative methodologies, including adaptive and model-based approaches, to support efficient and agile drug development.
• Provide strategic input into drug development strategies in collaboration with program-level and functional leadership, working closely with Clinical Development, Clinical Operations, and Translational Medicine.
• Ensure the integrity, high quality and traceability of clinical trial data and the accuracy of all statistical analyses, leading to compliant deliverables in biometry.
• Lead and support biometrics interactions with global health authorities.
• Establish and maintain vendor partnerships ensuring quality and timely delivery of outsourced biometrics activities.

What you’ll need to be successful:

• Doctoral degree in Biostatistics or related field
• 15+ years of biometrics experience within the biotech or pharmaceutical field
• Proven track record of leading, building, and managing teams
• Demonstrated ability to foster creativity, productivity, and execution with urgency, teamwork and accountability
• A leader who collaborates across departments, levels, and groups to achieve key objectives
• Deep knowledge of clinical trial design, regulatory requirements, and the statistical environment
• Excellent problem-solving skills, strategic thinking, and ability to work in a fast-paced, collaborative environment
• Outstanding interpersonal skills, self-awareness, and ability to manage team dynamics
• Ideally, has worked in more than one therapeutic area and has direct experience with innovative Phase 1-3 oncology clinical study designs
• Comfort with model-based drug development and agile drug development
• Appreciation for observational methodologies
• Ability to articulate complex methodologies to senior executives; prior experience presenting to senior executives is ideal
• Demonstrated use of AI tools in current role; advanced or innovative use of AI is a strong plus

Core Values:

• Growth-Minded. We’re inventing a new class of medicines—one applicable to therapeutic targets that have been dreamt about, but always considered impossible to drug. Our work requires us to be curious, humble and adaptable.
• In(ter)dependent. We are fiercely independent as a leader in defying the limitations of current therapeutic modalities, and interdependent as a team as we work collaboratively to shift drug discovery paradigms and provide patients with better treatment options.
• Patient-focused. We are deeply focused on patient outcomes, and all energy in the company is focused on science as it translates to patient impact.
• All-In. We’re All-In on solving some of the hardest scientific challenges and delivering one of the most effective new classes of drugs in history.

The base salary range for this position is $340,000-$380,000 per year, depending on experience, qualifications, and internal practices. Parabilis’s total compensation package also includes an annual target bonus, equity, and a comprehensive suite of competitive benefits designed to support our employees’ overall well-being.

As an equal opportunity employer, Parabilis values an inclusive workplace and welcomes applicants of all backgrounds and experiences. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law.